Kaleido Biosciences, Inc.
KLDOOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$4262
P/E Ratio—
52W High$0.19
52W Low$0.00001
Kaleido Biosciences, Inc. (KLDO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KLDO · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2021-12 | 2020-12 | 2019-12 | 2018-12 | 2017-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.10M | $0.97M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $2.36M | $0.06M | $1.32M | $0.00M | $0.00M |
| Gross Profit | ($1.25M) | ($54.99M) | ($1.32M) | $0.00M | $0.00M |
| Gross Margin %(computed) | -113.59% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $67.80M | $55.97M | $64.23M | $42.06M | $20.99M |
| G&A Expenses | $20.97M | $23.88M | $22.43M | $18.62M | $6.04M |
| Total Operating Expenses | $86.41M | $23.88M | $86.66M | $60.68M | $27.03M |
| Operating Income | ($87.67M) | ($78.87M) | ($86.66M) | ($60.68M) | ($27.03M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.07M | $0.25M | $1.69M | $1.12M | $0.03M |
| Interest Expense | $2.84M | $2.80M | $0.98M | $1.00M | $0.43M |
| Income Before Tax | ($90.29M) | ($81.62M) | ($86.33M) | ($61.74M) | ($27.56M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | ($0.06M) | ($0.09M) |
| Net Income | ($90.29M) | ($81.62M) | ($85.01M) | ($61.74M) | ($27.56M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.16 | $-2.44 | $-3.31 | $-2.10 | $-1.23 |
| Wtd Avg Shares | 41.86M | 33.45M | 25.70M | 29.39M | 22.42M |
| EBITDA | ($85.09M) | ($77.00M) | ($84.04M) | ($59.03M) | ($26.70M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Kaleido Biosciences, Inc. data
About Kaleido Biosciences, Inc. (KLDO) Income Statement
Kaleido Biosciences, Inc. (KLDO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2021, KLDO reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -113.59%), and net income of ($0.09B) — a net profit margin of -8178.26%.
Frequently asked questions
KLDO · 4 questionsKaleido Biosciences, Inc. (KLDO) reported revenue of $0.00B for 2021, up 13.2% year-over-year.
KLDO revenueKLDO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08